Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature

Valentina Tabanelli1, Claudio Agostinelli1, Elena Sabattini1, Anna Gazzola1, Francesco Bacci1, Saveria Capria2, Claudia Mannu1, Simona Righi1, Maria Teresa Sista1, Giovanna Meloni2, Stefano A Pileri1 and Pier Paolo Piccaluga1*

Abstract

Introduction: Systemic Epstein-Barr-virus-positive T cell lymphoproliferative disease of childhood is an extremely rare disorder, characterized by clonal proliferation of Epstein-Barr-virus-infected T cells with an activated cytotoxic phenotype. The disease is more frequent in Asia and South America, with only few cases reported in Western countries. A prompt diagnosis, though often difficult, is a necessity due to the very aggressive clinical course of the disease.

Case presentation: We report the clinicopathological features of fulminant T cell lymphoproliferative disease that arose in the setting of acute primary Epstein-Barr virus infection. Our patient, a 23-year-old man, presented to our facility with persisting fever, hepatosplenomegaly and severe pancytopenia. On bone marrow biopsy, an abundant lymphoid infiltrate was observed. Immunophenotypic and molecular studies revealed that the atypical lymphoid cells displayed a CD8+ Epstein-Barr-encoded-RNA-positive T cell phenotype with clonal rearrangement of the T cell receptor genes, the final diagnosis being systemic Epstein-Barr-virus-positive T cell lymphoproliferative disease. On reviewing the literature we found only 14 similar cases, all presenting with very aggressive clinical courses and requiring extensive phenotyping and molecular techniques for final diagnosis.

Conclusion: Though extremely rare, this disease can occur in Europe, and a comprehensive diagnostic approach is thus recommended in all case of Epstein-Barr-virus-positive lymphoproliferative disorders. Unfortunately, at present no specific treatment is available; however, prompt administration of anti- Epstein-Barr virus treatment and rapid attempts to control the hemophagocytic syndrome are indicated.

Introduction

Primary infection of Epstein-Barr virus (EBV) is commonly asymptomatic, but some children, adolescents and young adults develop infectious mononucleosis [1] (IM), a benign febrile disease characterized by hepatosplenomegaly, lymphadenopathy, and increase of activated CD8 + T lymphocytes in peripheral blood [1,2]. However, exceptionally, younger patients can develop a very aggressive form, referred to in the past as ‘fulminant infectious mononucleosis’ or ‘fatal haemophagocytic syndrome’. The disorder is characterized by rapid deterioration in previously healthy children, secondary to acute primary EBV infection; this syndrome is accompanied by high fever, skin rash, pulmonary infiltrate, jaundice, hepatosplenomegaly, cytopenia, haemophagocytic syndrome, and coagulopathy [3]. Unfortunately, patients commonly die within a few weeks of diagnosis.

In addition, EBV is implicated in the pathogenesis of different types of lymphoproliferative diseases (LPD), which are related to diverse immune alterations or peculiar clinical backgrounds [4]. Typically, EBV-associated lymphoproliferative disorders are derived from B cells, such as Hodgkin disease and Burkitt lymphoma.
where memory B cells are the physiological reservoir of latent EBV [1]. Nonetheless, rare EBV-driven T cell tumors have been recognized.

In this regard, fulminant mononucleosis has recently been demonstrated to be a monoclonal CD8⁺ LPD, and is currently classified as systemic EBV⁺ T cell LPD of childhood in the World Health Organization classification of tumors of hematopoietic and lymphoid tissues [5]. This entity is a rare clonal proliferation of EBV-infected T cells with an activated cytotoxic phenotype [5]; the disease occurs with increased frequency in immunocompetent children and young adults, appears to be more common in Asians and Native Americans, and is associated with rapid progression, high morbidity and mortality. It can develop after primary EBV infection or in association with chronic active EBV infection (CAEBV). Despite the name, the disease occurs not only in children but in adolescent and young adults as well, the median age being around 20 years [5].

At morphology, neoplastic T cells are usually small and lack significant cytological atypia [6]. However, cases with pleomorphic medium-sized to large-sized lymphoid cells, irregular nuclei and frequent mitoses have been described. The most typical phenotype is CD2⁺, CD3⁺, CD8⁺, CD56⁻, and TIA⁺ [6-8]; conversely, cases arising in the setting of severe CAEBV are CD4⁺. Neoplastic cells have monoclonally rearranged T cell receptor (TCR) genes, and consistent Epstein-Barr encoded RNA (EBER) positivity at in situ hybridization (ISH). Differential diagnosis mainly concerns reactive conditions as well as aggressive natural killer (NK) cell leukemia.

Here, we report the clinicopathological features of fulminant T-LPD that arose in the setting of acute primary EBV infection in our patient, characterized by a monoclonal proliferation of EBV-infected T cells.

**Case presentation**

A 23-year-old Caucasian man was hospitalized for persisting fever resistant to conventional therapies. On physical examination, our patient presented with marked hepatosplenomegaly and abnormal sounds at thoracic auscultation. Laboratory findings consisted of severe pancytopenia (hemoglobin 9.3 g/dL, platelets 93 × 10⁹ cells/L, white blood cells 2.2 × 10⁹ cells/L, neutrophils 410 × 10⁹ cells/L, lymphocytes 1.570 × 10⁹ cells/L), increased LDH, signs of disseminated intra-vascular coagulopathy (CID), and anti-EBV IgM positivity, while a chest X-ray showed diffuse pulmonary infiltrates. No prior immunological abnormalities were recorded.

For the suspicion of either massive bone marrow infiltration by leukemia/lymphoma or hemophagocytic syndrome a bone marrow biopsy was performed. Results from the biopsy showed the bone marrow was hypercellular, with numerous atypical lymphoid cells and occasional hemophagocytes (identified by positive staining for CD68/PGM1) (Figure 1). Lymphocytes were more often small and without significant atypia; a smaller percentage was represented by larger cells (Figures 1 and 2). Immunohistochemistry (IHC) investigation results showed atypical lymphocytes were CD79α⁺, CD3⁺, CD2⁺, CD8⁺ and TIA1⁺ (Figure 2). ISH for EBER demonstrated that the majority of lymphoid cells were positive (Figure 2). Finally, polymerase chain reaction (PCR) analysis revealed a monoclonal rearrangement of the TCRγ genes. IHC, ISH and molecular analyses were carried out as previously described [9,10].

Based on the above findings, a final diagnosis of systemic EBV⁺ T cell LPD of childhood was made. Our patient was initially treated with two sequential doses of VP16 with moderate improvement of his clinical and laboratory data. In particular, the fever transiently improved, hepatosplenomegaly was reduced, and coagulation parameters were partially corrected; however, severe peripheral blood cytopenia persisted. Soon after, the patient developed a fever recrudescence in association with pulmonary fungal infection.
A second bone marrow biopsy was performed, revealing (hypo)aplasia with a minimum percentage of CD79a+, CD3+, CD4−, CD8+, EBER− small lymphocytes and absence of the previously observed CD8+ large cells. VP16 was then replaced with cyclosporine, obtaining a white blood cell count increase and a further decline of splenomegaly, but with no improvement in thrombocytopenia. A third bone marrow biopsy showed an increased cellularity with reappearance of numerous CD8+ lymphocytes and evident hemophagocytosis.

Our patient then developed rectal hemorrhages only treatable with surgery, which turned out to be sustained by microvascular thrombosis on histological examination. Finally, after a short period of relative good health, our patient had a relapse of rectal bleeding and died soon after with cerebral manifestations.

**Discussion**

Systemic EBV+ T cell LPD of childhood is a rare disorder characterized by an aggressive disease course and dismal prognosis [5]. As death unfortunately often occurs within a few weeks, and at present there is no specific treatment, a prompt diagnosis is necessary. Our case report highlights the fact that, though rare, such a disease can occur also in Europe.

On reviewing the literature, we found only 14 cases reported in Western countries [6,11-14], specifically cases recorded in Europe and the USA (Table 1). Interestingly, the majority of cases have been reported in eastern Asia [5], specifically in Japan and Taiwan. The geographical distribution has been suggested to indicate possible genetically determined defects in T cell responses to EBV in certain populations.

Our review of Western cases showed that four of those 14 patients developed a T cell LPD after CAEBV infection [6,11], and 10 presented a fulminant EBV T cell LPD following acute EBV infection. In the former group, ethnic origin was specified only in one case (white); in the latter group, one patient was of Caucasian descent, four were Asian or Native American, while in five cases the ethnic group was not specified. Mean age at onset was 17 years and the male/female ratio was 2.3:1. Common symptoms were fever, hepatosplenomegaly and hematophagocytic syndrome; the clinical courses were fulminant in patients with T cell LPD after acute IM. In particular, in the acute IM group three cases had a CD8+ phenotype, two a CD4+ phenotype and one showed double positivity for CD8 and CD4; in one case phenotype was not interpretable and in three cases it was not reported. TCRα presented with clonal rearrangements in nine out of 10 patients and EBV genome was clonal in all but one case. In contrast, among patients with T cell LPD after CAEBV infection two were CD4+, one was CD45RO+ and one presented with an admixture of CD8+ and CD4+ lymphocytes; three cases presented with monoclonal patterns with regard to rearrangement of both TCRα genes and EBV genome. In the remaining case, only the EBV positivity was assessed.

In all described cases, an accurate diagnostic investigation including clinical, morphological, immunohistochemical, and molecular analyses was necessary in order to formulate a correct diagnosis. In particular, the differential diagnosis with aggressive NK cell leukemia was based on surface sCD3 and CD8 positivity, CD56 negativity, and evidence of TCRα rearrangement in systemic EBV+ T cell LPDs, and also sCD3/CD8 negativity, CD56 positivity and germline TCRα patterns in aggressive NK cell leukemia cases.

**Conclusion**

In conclusion, our case report underlines the importance of a comprehensive diagnostic approach in the management of atypical EBV+ LPDs. In fact, though, at present, specific therapies are not available, the correct
Table 1 Cases of systemic Epstein-Barr virus positive (EBV⁺) T cell lymphoproliferative disease (LPD) of childhood described in Western countries

| Reference        | Age/sex | Race      | Case description                                      | Time to lymphoma | Histopathological features                                      | TCR status          | EBV status    |
|------------------|---------|-----------|-------------------------------------------------------|------------------|----------------------------------------------------------------|---------------------|---------------|
| Jones et al. [11] | tw/o/M  | Unspecified| Fever, generalized erythematous skin eruption,       | six years        | Pulmonary large cell lymphoma (phenotype: CD4⁺, HLA-DR⁺)       | TCRβ⁺ rearranged   | EBV⁺ clonal   |
|                  |         |           | hepatitisplenomegaly, pancytopenia, hypocellular      |                  |                                                                | EBV⁺ clonal         |               |
|                  |         |           | bone marrow, pulmonary infiltrates                    |                  |                                                                |                     |               |
|                  | 31/F    | Unspecified| Fever, generalized lymphadenopathy,                  | one year         | Lymphoblastic lymphoma (phenotype: CD4⁺, HLA-DR⁺)               | TCRβ⁺ γ rearranged | EBV⁺ clonal   |
|                  |         |           | hepatitisplenomegaly, pancytopenia, diarrhoea,       |                  |                                                                | EBV⁺ clonal         |               |
|                  |         |           | gastric pain                                          |                  |                                                                |                     |               |
|                  | 55/M    | Unspecified| Glutent enteropathy for 19 years; fever, persistent | one year         | Peripheral T cell lymphoma (phenotype: UCHL1⁺)                 | -                   | EBV⁺          |
|                  |         |           | diarrhoea, nodular erythematous skin lesion          |                  |                                                                |                     |               |
| Gaillard et al.  [13] | seven/F | Unspecified| Infectious acute mononucleosis, persistent high-     | four months      | Fulminant EBV⁺ T cell LPD (phenotype: CD8⁺)                    | TCRβ⁺ γ rearranged | EBV⁺ clonal   |
|                  |         |           | grade fever, weight loss, adenopathy, necrotizing    |                  |                                                                | EBV⁺ clonal         |               |
|                  |         |           | skin lesions and VAHS                                 |                  |                                                                |                     |               |
| Craig et al. [15] | 20      | Unspecified| Fever, generalized erythematous skin eruption,       | -                | T cell lymphoma NOS (phenotype: not interpretable)             | TCRβ⁺ rearranged   | EBV⁺ clonal   |
|                  | months/ |           | hepatitisplenomegaly                                  |                  |                                                                | EBV⁺ clonal         |               |
|                  | F       |           |                                                        |                  |                                                                |                     |               |
| Quintanilla-     | 37/M    | Native American | Fever, mental status of one week duration,           | -                | Fulminant EBV⁺ T cell LPD (phenotype: CD8⁺, TIA1⁺)             | TCRγ⁻ rearranged   | EBV⁺ clonal   |
| Martinez et al.  [6] |         |           | hepatitisplenomegaly, pancytopenia, jaundice         |                  |                                                                | EBV⁺ clonal         |               |
|                  | 17/M    | Native American | Symptoms of viral upper respiratory illness,         | -                | Fulminant EBV⁺ T cell LPD (phenotype: CD8⁺, TIA1⁺)             | TCRγ⁻ rearranged   | EBV⁺ clonal   |
|                  |         |           | hepatitisplenomegaly, pancytopenia, jaundice         |                  |                                                                | EBV⁺ clonal         |               |
|                  | 23/M    | Asian     | Fever, night sweats, weight loss,                     | -                | Fulminant EBV⁺ T cell LPD (phenotype: CD4⁺, CD8⁺, TIA1⁺)       | TCRγ⁻ rearranged   | EBV⁺ clonal   |
|                  |         |           | hepatitisplenomegaly, pancytopenia, jaundice,         |                  |                                                                | EBV⁺ clonal         |               |
|                  |         |           | generalized lymphadenopathy                           |                  |                                                                |                     |               |
|                  | 22/F    | Native American | Fever weight loss, hepatitisplenomegaly,             | -                | Fulminant EBV⁺ T cell LPD (phenotype: CD4⁺, TIA1⁺)             | Polyclonal          | EBV⁺ clonal   |
|                  |         |           | jaundice                                              |                  |                                                                |                     |               |
|                  | 27      | Native American | Fever, skin rash, hepatitisplenomegaly,              | -                | Fulminant EBV⁺ T cell LPD (phenotype: CD8⁺, TIA1⁺)             | TCRγ⁻ rearranged   | EBV⁺ clonal   |
|                  | months/ |           | pancytopenia                                          |                  |                                                                | EBV⁺ clonal         |               |
|                  | M       |           |                                                        |                  |                                                                |                     |               |
|                  | 15/F    | White     | IM at eight years old, followed by CAEBV. At 14      | -                | Fulminant EBV⁺ T cell LPD (phenotype: CD4⁺, CD8⁺, TIA1⁺)       | TCRγ⁻ rearranged   | EBV⁺ clonal   |
|                  |         |           | years old developed hepatitisplenomegaly and         |                  |                                                                | EBV⁺ clonal         |               |
|                  |         |           | hemophagocytic syndrome                               |                  |                                                                |                     |               |
| Wick et al. [14] | 12/M    | Unspecified| Hemophagocytic syndrome, FIM                          | -                | Fulminant EBV⁺ T cell LPD (phenotype: not reported)             | TCRβ⁺ γ rearranged | EBV⁺ clonal   |
|                  |         |           |                                                        |                  |                                                                | EBV⁺ clonal         |               |
|                  | three/F | Unspecified| Hemophagocytic syndrome, FIM                          | -                | Fulminant EBV⁺ T cell LPD (phenotype: not reported)             | TCRβ⁺ γ rearranged | EBV⁺ clonal   |
|                  |         |           |                                                        |                  |                                                                | EBV⁺ clonal         |               |
|                  | nine/M  | Unspecified| Hemophagocytic syndrome, FIM                          | -                | Fulminant EBV⁺ T cell LPD (phenotype: not reported)             | TCRβ⁺ γ rearranged | EBV⁺ clonal   |

CAEBV = chronic active EBV infection; FIM = fatal infectious mononucleosis; HLA = human leukocyte antigen; IM = infectious mononucleosis; NOS = not otherwise specified; TCR = T cell receptor; VAHS = virus-associated hemophagocytic syndrome.

A description of rare disorders is essential for improving current knowledge and possibly future therapeutic approaches.

Consent
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Acknowledgements
This work was supported by Centro Interdipartimentale per la Ricerca sul Cancro ‘G Prodi’, Bologna, AIRC (IG4987, IG1007, and 5xMille), RFO (to SAP and PPP), Fondazione Cassa di Risparmio in Bologna, Fondazione della Banca del Monte e Ravenna, Progetto Strategico di Ateneo 2006 (to SAP and PPP).

Author details
1Department of Hematology and Oncological Sciences ‘L and A Seràgnoli’, Hematopathology Section, S Orsola-Malegpi Hospital, University of Bologna, Bologna, Italy. 2Hematology, Department of Cellular Biotechnologies and Hematology, ‘Sapienza’ University, Rome, Italy.
Authors’ contributions
VT performed research, analyzed data and wrote the manuscript; CA performed research and analyzed data; ES and FB analyzed data; SC and GM were responsible for patient care and provided clinical information; AG, CM, SR, and MTS analyzed data; SAP and PPP performed research, analyzed data and wrote the manuscript. All authors read and approved the final manuscript. VT and CA contributed equally to this work; SAP and PPP contributed equally to this work.

Competing interests
The authors declare that they have no competing interests.

Received: 18 August 2010 Accepted: 7 June 2011
Published: 7 June 2011

References
1. Straus SE, Cohen JI, Tosato G, Meier J: NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 1993, 118:65-68.
2. Callan MF, Steven N, Krausa P, Wilson JD, Moss PA, Gillespie GM, Bell JL, Richardson AB, McMichael AJ: Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med 1996, 2:906-911.
3. Ohshima K, Kimura H, Yoshino T, Kim CW, Ko YH, Lee SS, Peh SC, Chan JK: Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int 2008, 58:209-217.
4. Carbone A, Gloghini A, Dotti G: EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 2008, 13:577-585.
5. Quintanilla-Martinez L, Kimura H, Jaffe E: EBV+ T-cell lymphoproliferative disorders of childhood. In WHO Classification of Tumors of Hematopoetic and Lymphoid Tissues. 4 edition. Edited by: Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman J. Lyon: IARC; 2008.
6. Quintanilla-Martinez L, Martinez M, Kumar S, Fend E, Reyes E, Teruya-Feldstein J, Kingma DW, Sorbara L, Raffeld M, Straus SE, Jaffe ES: Fulminant EBV+ T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood 2000, 96:443-451.
7. Kasahara Y, Yachie A, Takei K, Kanegane C, Okada K, Ohta K, Seki H, Igarashi N, Maruhashi K, Katayama K, Katoh E, Terao G, Sakayama Y, Koizumi S: Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001, 98:1882-1888.
8. Su U, Chen RL, Lin DT, Lin KS, Chen CC: Epstein-Barr virus (EBV) infects T lymphocytes in childhood EBV-associated hematoproliferative syndrome in Taiwan. Am J Pathol 1994, 144:1219-1225.
9. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, Delabalée E, Davi F, Schuuring E, Garcia-Sanz R, van Krieken JH, Driese J, González D, Bastard C, White HE, Spaargaeren M, González M, Pareira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA: Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003, 17:2257-2317.
10. Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, Bacci F, Falini B, Motta T, Artusi T, Piccioli M, Zinzani PL, Pileri SA: Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006, 24:2472-2479.
11. Jones JF, Shurin S, Abramowsky C, Tubbs RR, Scotto CG, Wahl R, Sands J, Gottmann D, Katz BZ, Sklar J: T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. New Engl J Med 1988, 318:733-741.
12. Doležal MV, Kamei CW, van de Bijn M, Mealy ML, Sibley RK, Warneke RA: Virus-associated hemophagocytic syndrome characterized by clonal Epstein-Barr virus genome. Am J Clin Pathol 1995, 103:189-194.
13. Gaillard F, Mechinaud-Lacroix F, Papin S, Moreau A, Mollat C, Fiche M, Pelletier S, De Faujaux PJ, Rousselet MC, Praloran V, et al: Primary Epstein-Barr virus infection with clonal T-cell lymphoproliferation. Am J Clin Pathol 1992, 98:324-333.
14. Wick MJ, Wortonoff-Dashoff KP, McGlennen RC: The molecular characterization of fatal infectious mononucleosis. Am J Clin Pathol 2002, 117:582-588.
15. Craig FE, Gulley ML, Banks PM: Posttransplantation lymphoproliferative disorders. American journal of clinical pathology 1993, 99:265-276.

Cite this article as: Tabanelli et al: Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature. Journal of Medical Case Reports 2011 5:218.